Akinseye Oluwaseun A, Shahreyar Muhammad, Heckle Mark R, Khouzam Rami N
Department of Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Ann Transl Med. 2018 Jan;6(1):7. doi: 10.21037/atm.2017.11.06.
Acute ischemic stroke (AIS) and acute myocardial infarction (AMI) are both life-threatening medical conditions with narrow therapeutic time-window that carry grave prognosis if not addressed promptly. The acute management of both condition is well documented in the literature, however the management of a simultaneous presentation of both AIS and AMI is unclear. A delayed intervention of one infarcted territory for the other may result in permanent irreversible morbidity or disability, and even death. In addition, the use of antiplatelet and anticoagulants that are inherently part of an AMI management may increase the risk for hemorrhagic conversion associated with intravenous thrombolysis used in AIS, and the use of a thrombolytic in AIS increases the risk of cardiac wall rupture in the setting of an AMI. Despite this ambiguity, there is no clear evidence-based guideline or clinical studies that have addressed the optimal management of this rare co-occurrence. This review paper examines the existing literature on the management of simultaneous acute cardio-cerebral infarction (CCI) and highlights the existing challenge to management.
急性缺血性卒中(AIS)和急性心肌梗死(AMI)均为危及生命的疾病,治疗时间窗狭窄,若不及时处理,预后严重。这两种疾病的急性处理在文献中有充分记载,但AIS和AMI同时出现时的处理尚不明确。对一个梗死区域的延迟干预可能会导致另一个梗死区域出现永久性不可逆的发病或残疾,甚至死亡。此外,AMI治疗中固有的抗血小板和抗凝药物的使用可能会增加与AIS静脉溶栓相关的出血转化风险,而AIS中使用溶栓药物会增加AMI情况下心脏壁破裂的风险。尽管存在这种不确定性,但尚无明确的循证指南或临床研究涉及这种罕见共病的最佳处理。本文综述探讨了关于同时发生的急性心脑梗死(CCI)处理的现有文献,并强调了目前处理面临的挑战。